Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome

• Status: Active, not recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

Health organizations recommend exercise in an intensity based manner to promote cardiovascular adaptation and prevent disease. Metformin is a common anti-diabetes medication that reduces future type 2 diabetes and cardiovascular disease (CVD) risk. However, the optimal dose of exercise to be combined with metformin for vascular health remains unknown. The purpose of this study is to evaluate whether combining high or low intensity exercise with metformin has the potential to outperform either exercise intensity alone on blood flow across the arterial tree as well as impact insulin action in individuals with metabolic syndrome. Identification of such outcomes will indicate 1) whether and how metformin should be combined with physical activity for CVD prevention, 2) provide the first indication of whether exercise intensity reduces CVD risk via multi-level vasculature function vs. metabolic insulin action, and 3) provide a rational early treatment for people with metabolic syndrome to prevent/treat type 2 diabetes and CVD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rutgers University; University of Virginia
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Male or female >40 and <70 years old.

• Has a body mass index >27 and <47 kg/m2.

• Not diagnosed with Type 2 diabetes.

• Not currently engaged in > 60 min/wk of exercise

• Meet at least 3 of 5 National Cholesterol Education Adult Treatment Panel III

Metabolic Syndrome criteria:

• Increased waist circumference (≥102 cm in men; ≥88 cm in women)

• Elevated triglycerides (≥150 mg/dl), or on medication for treating the condition

• Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication for treating the condition

• High blood pressure (≥130 mmHg systolic or ≥85mmHg diastolic), or on medication for treating the condition

• Elevated fasting glucose (≥100 mg/dl), or on medication for treating the condition

Exclusion Criteria:

• Morbidly obese patients (BMI >47 kg/m2) and overweight/lean patients (BMI <27 kg/m2)

• Evidence of type 1 diabetes and diabetics requiring insulin therapy.

• Subjects who have not been weight stable (>2 kg weight change in past 3 months)

• Subjects who have been recently active (>30 min of moderate/high intensity exercise, 2 times/week).

• Subjects who are smokers or who have quit smoking <5 years ago

• Subjects prescribed metformin or have taken metformin within 1 year.

• Subjects with abnormal estimated glomerular filtration rate (eGFR).

• Hypertriglyceridemic (>400 mg/dl) and hypercholesterolemic (>260 mg/dl) subjects

• Hypertensive (>160/100 mmHg)

• Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).

• Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety.

• Pregnant (as evidenced by positive pregnancy test) or nursing women

• Subjects with contraindications to participation in an exercise training program

• Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzephetamine, diethylpropion, phendimetrazine)

• Known hypersensitivity to perflutren (contained in Definity)